Amicus Therapeutics Q3 EPS $(0.07) Beats $(0.08) Estimate, Sales $103.50M Beat $101.36M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics reported Q3 earnings per share (EPS) of $(0.07), beating the analyst consensus estimate of $(0.08) by 12.5%. This is a 41.67% increase over the same period last year. The company also reported quarterly sales of $103.50 million, beating the analyst consensus estimate of $101.36 million by 2.11%. This is a 26.70% increase over the same period last year.
November 08, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amicus Therapeutics reported better than expected Q3 earnings and sales, showing significant YoY growth.
Amicus Therapeutics reported Q3 earnings and sales that beat analyst estimates, which is typically a positive signal for the stock. The YoY growth in both earnings and sales also indicates that the company's financial performance is improving, which could further boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100